

Please amend the claims as follows:

1-21. Canceled

22. (Currently amended) An isolated polypeptide consisting of X1-SHCIX2-X3 **(SEQ ID NO:104)**

wherein X1 is 0-10 **contiguous** amino acids of the sequence ATTAGILATL (SEQ ID NO:41), **wherein X1 is contiguous with SHCIX2 from the X1 C-terminus;**

X2 is E or Q; and

[X2] **X3** is 0-10 **contiguous** amino acids of the sequence LMVKREDSWQ (SEQ ID NO:42), **wherein X3 is contiguous with SHCIX2 from the X3 N-terminus.**

23. Canceled

24. (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim 22 and a pharmaceutically acceptable carrier.

25-33. Canceled

34. (Previously presented) The isolated polypeptide of claim 22 wherein X2 is E.

35. (Previously presented) The isolated polypeptide of claim 22 wherein X2 is Q.

36. (Currently amended) The isolated polypeptide of claim 22 wherein [X1 is ILATL] **the polypeptide consists of ILATLSHCIELMVKR (SEQ ID NO: 43).**

37. (Currently amended) The isolated polypeptide of claim 22 wherein [X3 is LMKVR] **the polypeptide consists of ILATLSHCIQLMVKR (SEQ ID NO: 44).**

38. (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim 34 and a pharmaceutically acceptable carrier.

39. (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim 35 and a pharmaceutically acceptable carrier.

40. (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim 36 and a pharmaceutically acceptable carrier.

41. (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim 37 and a pharmaceutically acceptable carrier.

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

Please replace the paragraph on page 33, lines 15-21 with the following paragraph:

As part of the present invention, the inventors have identified further inhibitors of GPBP activity. Thus, in another aspect, the present invention provides an isolated polypeptide consisting of an amino acid sequence according to the general formula X1-SHCIX2-X3 **(SEQ ID NO:104)**, wherein:

X1 is 0-10 amino acids of the sequence ATTAGILATL (SEQ ID NO:41);

X2 is E or Q; and

X3 is 0-10 amino acids of the sequence LMVKREDSWQ (SEQ ID NO:42).